

Media Release

2 June 2020

PHARMAXIS TO PRESENT AT MONSOON COMMUNICATIONS WEBINAR

Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips will present at the Monsoon Communications Webinar on Wednesday 3 June 2020 at 11:00am AEST. The webinar will be hosted by David Blake, publisher of Bioshares and will feature presentations by Mr Phillips and Opthea CEO & Managing Director Dr Megan Baldwin.

Shareholders and investors are invited to participate in this free event.

The event is free and investors should register in advance to participate using the following registration link:

https://us02web.zoom.us/webinar/register/WN_1WHGL760Tsa2nxWO98c3KQ?mc_cid=cb47f079b0&mc_eid=5820d91b14

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:

David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203,
E david.mcgarvey@pharmaxis.com.au

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737,
E rudim@monsoon.com.au

About Pharmaxis

Pharmaxis Limited is an Australian pharmaceutical research company and a global leader in drug development for inflammation and fibrotic diseases. The company has a highly productive drug discovery engine, drug candidates in clinical trials and significant future cash flows from partnering deals.

Leveraging its small-molecule expertise and proprietary amine oxidase chemistry platform, Pharmaxis has taken four in-house compounds to Phase 1 trials in just five years. Boehringer Ingelheim acquired the Pharmaxis anti-inflammatory AOC3 inhibitor in 2015 to develop it (BI 1467335) for two diseases: the liver condition Non-alcoholic Steatohepatitis (NASH) and diabetic retinopathy (DR).

The company's successor amine oxidase program has developed an oral anti-fibrotic LOXL2 inhibitor, aimed at NASH, pulmonary fibrosis (IPF) and other high-value fibrotic heart and kidney diseases, with a commercial partnering process underway, a systemic pan-LOX inhibitor for acute fibrosis and cancer that will enter a phase 2 study in 2020 and a topical pan-LOX inhibitor for scarring that is expected to commence phase 1 studies in 2H 2020. Pharmaxis' Mannitol platform has yielded the products Bronchitol® for cystic fibrosis, which is marketed in Europe, Russia and Australia, with United States FDA approval pending; and Aridol® for the assessment of asthma, which is sold in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. <http://www.pharmaxis.com.au/>